Stefano Perlini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2548156/publications.pdf

Version: 2024-02-01

176 papers 9,400 citations

41344 49 h-index 92 g-index

179 all docs

179 docs citations

179 times ranked 12453 citing authors

#	Article	IF	Citations
1	A national survey on prevalence of possible echocardiographic red flags of amyloid cardiomyopathy in consecutive patients undergoing routine echocardiography: study design and patients characterization — the first insight from the AC-TIVE Study. European Journal of Preventive Cardiology, 2022, 29, e173-e177.	1.8	21
2	Mortality due to COVID-19 during the pandemic: A comparison of first, second and third SMAtteo COvid19 REgistry (SMACORE). Heliyon, 2022, 8, e08895.	3.2	2
3	Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the <scp>AC‶VE</scp> study, an <scp>Italian nationwide survey</scp> . European Journal of Heart Failure, 2022, 24, 1377-1386.	7.1	43
4	Obeticholic Acid Reduces Kidney Matrix Metalloproteinase Activation Following Partial Hepatic Ischemia/Reperfusion Injury in Rats. Pharmaceuticals, 2022, 15, 524.	3.8	1
5	MCD Diet Rat Model Induces Alterations in Zinc and Iron during NAFLD Progression from Steatosis to Steatohepatitis. International Journal of Molecular Sciences, 2022, 23, 6817.	4.1	8
6	Lung-ultrasound objective structured assessment of technical skills (LUS-OSAUS): utility in the assessment of lung-ultrasound trained medical undergraduates. Journal of Ultrasound, 2021, 24, 57-65.	1.3	8
7	Time for a new international evidenceâ€based recommendations for pointâ€ofâ€care lung ultrasound. Journal of Ultrasound in Medicine, 2021, 40, 433-434.	1.7	7
8	Vitamin D 250H deficiency in COVID-19 patients admitted to a tertiary referral hospital. Clinical Nutrition, 2021, 40, 2469-2472.	5.0	68
9	New effective treatment options reinforce disease awareness: the case of transthyretin cardiac amyloidosis. European Journal of Heart Failure, 2021, 23, 290-292.	7.1	1
10	Middle-aged Man Recovering from COVID-19 Pneumonia. Annals of Emergency Medicine, 2021, 77, e85-e86.	0.6	0
11	Lung ultrasound for the early diagnosis of COVID-19 pneumonia: an international multicenter study. Intensive Care Medicine, 2021, 47, 444-454.	8.2	122
12	The role of emergency medicine residents during the global SARS-Cov-2 pandemic: The Pavia experience. Emergency Care Journal, $2021,17,.$	0.3	1
13	Lung ultrasound presentation of COVID-19 patients: phenotypes and correlations. Internal and Emergency Medicine, 2021, 16, 1317-1327.	2.0	18
14	Clinical factors associated with death in 3044 COVID-19 patients managed in internal medicine wards in Italy: results from the SIMI-COVID-19 study of the Italian Society of Internal Medicine (SIMI). Internal and Emergency Medicine, 2021, 16, 1005-1015.	2.0	37
15	Can Alveolar-Arterial Difference and Lung Ultrasound Help the Clinical Decision Making in Patients with COVID-19?. Diagnostics, 2021, 11, 761.	2.6	7
16	The Role of Lung Ultrasound in Lowâ€Resource Settings during the Coronavirus (SARS oV â€2) Pandemic. Journal of Ultrasound in Medicine, 2021, , .	1.7	3
17	From Clinical Clues to Final Diagnosis: The Return of Detective Work to Clinical Medicine in Cardiac Amyloidosis. Frontiers in Cardiovascular Medicine, 2021, 8, 644508.	2.4	11
18	High troponin levels in patients hospitalized for coronavirus disease 2019: a maker or a marker of prognosis?. Journal of Cardiovascular Medicine, 2021, 22, 828-831.	1.5	4

#	Article	IF	Citations
19	Patient adherence and comprehension of take-home anticoagulant regimens prescribed at the emergency department: preliminary findings from a randomized controlled trial and implications for patient safety. Internal and Emergency Medicine, 2021, , 1.	2.0	0
20	465â€∫Unmasking the prevalence of cardiac amyloidosis in the real world: first insights from the phase 2 of active study, an Italian nationwide survey. European Heart Journal Supplements, 2021, 23, .	0.1	0
21	Psychological Support in a COVID-19 Hospital: A Community Case Study. Frontiers in Psychology, 2021, 12, 820074.	2.1	5
22	Non-steroidal anti-inflammatory drug effects on renal and cardiovascular function: from physiology to clinical practice. European Journal of Preventive Cardiology, 2020, 27, 850-867.	1.8	22
23	Noncontrast Magnetic Resonance for theÂDiagnosis of Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 2020, 13, 69-80.	5.3	125
24	Multiparametric Echocardiography Scores for the Diagnosis of CardiacÂAmyloidosis. JACC: Cardiovascular Imaging, 2020, 13, 909-920.	5.3	136
25	Low Sensitivity of Bone Scintigraphy in Detecting Phe64Leu Mutation-Related Transthyretin Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 2020, 13, 1314-1321.	5.3	82
26	Gender differences in predictors of intensive care units admission among COVID-19 patients: The results of the SARS-RAS study of the Italian Society of Hypertension. PLoS ONE, 2020, 15, e0237297.	2.5	51
27	The Authors Reply:. JACC: Cardiovascular Imaging, 2020, 13, 1294-1295.	5.3	1
28	Eosinopenia could be a relevant prognostic biomarker in patients with coronavirus disease 2019. Allergy and Asthma Proceedings, 2020, 41, e80-e82.	2.2	18
29	Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1899-1913.	2.6	137
30	Cardiac involvement at presentation in patients hospitalized with COVID-19 and their outcome in a tertiary referral hospital in Northern Italy. Internal and Emergency Medicine, 2020, 15, 1457-1465.	2.0	32
31	Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study. European Journal of Internal Medicine, 2020, 82, 38-47.	2.2	88
32	Obeticholic acid reduces biliary and hepatic matrix metalloproteinases activity in rat hepatic ischemia/reperfusion injury. PLoS ONE, 2020, 15, e0238543.	2.5	9
33	Bedside wireless lung ultrasound for the evaluation of COVID-19 lung injury in senior nursing home residents. Monaldi Archives for Chest Disease, 2020, 90, .	0.6	17
34	On Lung Ultrasound Patterns Specificity in the Management of COVIDâ€19 Patients. Journal of Ultrasound in Medicine, 2020, 39, 2283-2284.	1.7	26
35	Lung Ultrasound in Patients with Acute Respiratory Failure Reduces Conventional Imaging and Health Care Provider Exposure to COVID-19. Ultrasound in Medicine and Biology, 2020, 46, 2090-2093.	1.5	61
36	Radiographic findings in 240 patients with COVID-19 pneumonia: time-dependence after the onset of symptoms. European Radiology, 2020, 30, 6161-6169.	4.5	93

3

#	Article	IF	CITATIONS
37	Transient Expression of Reck Under Hepatic Ischemia/Reperfusion Conditions Is Associated with Mapk Signaling Pathways. Biomolecules, 2020, 10, 747.	4.0	9
38	Lung ultrasound in COVID-19: a useful diagnostic tool. Emergency Care Journal, 2020, 16, .	0.3	10
39	Emergency Department and Out-of-Hospital Emergency System (112â€"AREU 118) integrated response to Coronavirus Disease 2019 in a Northern Italy centre. Internal and Emergency Medicine, 2020, 15, 825-833.	2.0	50
40	Is There a Role for Lung Ultrasound During the <scp>COVID</scp> â€19 Pandemic?. Journal of Ultrasound in Medicine, 2020, 39, 1459-1462.	1.7	369
41	Performance of VivaDiag COVIDâ€19 IgM/IgG Rapid Test is inadequate for diagnosis of COVIDâ€19 in acute patients referring to emergency room department. Journal of Medical Virology, 2020, 92, 1724-1727.	5.0	205
42	Proposal for International Standardization of the Use of Lung Ultrasound for Patients With <scp>COVID</scp> â€19. Journal of Ultrasound in Medicine, 2020, 39, 1413-1419.	1.7	483
43	SARS Cov-2 infection in a renal-transplanted patient: A case report. American Journal of Transplantation, 2020, 20, 1882-1884.	4.7	76
44	Baseline ECG Features and Arrhythmic Profile in Transthyretin Versus Light Chain Cardiac Amyloidosis. Circulation: Heart Failure, 2020, 13, e006619.	3.9	31
45	Myocarditis in a 16-year-old boy positive for SARS-CoV-2. Lancet, The, 2020, 395, e116.	13.7	52
46	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents. JAMA Pediatrics, 2020, 174, 882.	6.2	898
47	RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies. Vascular Pharmacology, 2020, 135, 106805.	2.1	39
48	Clinical characteristics of coronavirus disease (COVID-19) early findings from a teaching hospital in Pavia, North Italy, 21 to 28 February 2020. Eurosurveillance, 2020, 25, .	7.0	119
49	Associations between serum trace elements and inflammation in two animal models of nonalcoholic fatty liver disease. PLoS ONE, 2020, 15, e0243179.	2.5	6
50	Anterior cutaneous nerve block for analgesia in anterior chest trauma: is the parasternal approach necessary?. Clinical and Experimental Emergency Medicine, 2020, 7, 67-70.	1.6	4
51	Title is missing!. , 2020, 15, e0237297.		0
52	Title is missing!. , 2020, 15, e0237297.		0
53	Title is missing!. , 2020, 15, e0237297.		0
54	Title is missing!. , 2020, 15, e0237297.		0

#	Article	IF	CITATIONS
55	Title is missing!. , 2020, 15, e0237297.		O
56	Title is missing!. , 2020, 15, e0237297.		0
57	Beneficial effects of adaptive servo-ventilation on natriuretic peptides and diastolic function in acute heart failure patients with preserved ejection fraction and sleep-disordered breathing. Sleep and Breathing, 2019, 23, 287-291.	1.7	11
58	Realâ€world versus trial patients with transthyretin amyloid cardiomyopathy. European Journal of Heart Failure, 2019, 21, 1479-1481.	7.1	17
59	An evaluation of patisiran: a viable treatment option for transthyretin-related hereditary amyloidosis. Expert Opinion on Pharmacotherapy, 2019, 20, 2223-2228.	1.8	9
60	Fatty Acid Desaturase Involvement in Non-Alcoholic Fatty Liver Disease Rat Models: Oxidative Stress Versus Metalloproteinases. Nutrients, 2019, 11, 799.	4.1	17
61	Levobupivacaine combined with dexamethasone for serratus plane block can provide long-lasting analgesia in multiple rib fractures. Emergency Care Journal, 2019, 15, .	0.3	1
62	Animal Models of Steatosis (NAFLD) and Steatohepatitis (NASH) Exhibit Hepatic Lobe-Specific Gelatinases Activity and Oxidative Stress. Canadian Journal of Gastroenterology and Hepatology, 2019, 2019, 1-9.	1.9	17
63	The learning curve of sonographic inferior vena cava evaluation by novice medical students: the Pavia experience. Journal of Ultrasound, 2018, 21, 137-144.	1.3	13
64	Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies. Blood, 2018, 131, 525-532.	1.4	51
65	Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis. Circulation: Cardiovascular Imaging, 2018, 11, e006588.	2.6	51
66	The role of qSOFA compared to other prognostic scores in septic patients upon admission to the emergency department. European Journal of Internal Medicine, 2018, 53, e11-e13.	2.2	6
67	Ethnicity and Hypertension-Related Target Organ Damage. Updates in Hypertension and Cardiovascular Protection, 2018, , 95-103.	0.1	0
68	A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis. Blood, 2017, 129, 2120-2123.	1.4	76
69	Cardiovascular screening in low-income settings using a novel 4-lead smartphone-based electrocardiograph (D-Heart®). International Journal of Cardiology, 2017, 236, 249-252.	1.7	23
70	Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 54-55.	3.0	3
71	Response to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 56-57.	3.0	9
72	Patterns of relapse after upfront bortezomib therapy in AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 60-61.	3.0	2

#	Article	IF	Citations
73	Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides. European Journal of Heart Failure, 2017, 19, 710-717.	7.1	116
74	Lung ultrasound in internal medicine: A bedside help to increase accuracy in the diagnosis of dyspnea. European Journal of Internal Medicine, 2017, 46, 61-65.	2.2	30
75	Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells. Scientific Reports, 2017, 7, 15661.	3.3	63
76	Global Longitudinal Strain in master athletes and in hypertensive patients with the same degree of septal thickness. Scandinavian Journal of Medicine and Science in Sports, 2017, 27, 1411-1416.	2.9	4
77	New and Evolving Concepts Regarding the Prognosis and Treatment of Cardiac Amyloidosis. Current Heart Failure Reports, 2016, 13, 267-272.	3.3	8
78	Effects of a Bioavailable Arabinoxylan-enriched White Bread Flour on Postprandial Glucose Response in Normoglycemic Subjects. Journal of Dietary Supplements, 2016, 13, 626-633.	2.6	17
79	Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area. Journal of Neurology, 2016, 263, 916-924.	3.6	76
80	The burden of chronic noncommunicable diseases in undocumented migrants: a 1-year survey of drugs dispensation by a non–governmental organization in Italy. Public Health, 2016, 141, 26-31.	2.9	21
81	Ventricular–arterial coupling in the clinical evolution of acute ischemic stroke. Journal of Hypertension, 2016, 34, 2335-2336.	0.5	0
82	Vascular alterations in apolipoprotein A-I amyloidosis (Leu75Pro). A case–control study. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2015, 22, 187-193.	3.0	4
83	Echocardiographic and Biohumoral Characteristics in Patients With <scp>AL</scp> and <scp>TTR</scp> Amyloidosis at Diagnosis. Clinical Cardiology, 2015, 38, 69-75.	1.8	32
84	NT-proBNP and the risk of incident hypertension. Journal of Hypertension, 2015, 33, 924-925.	0.5	3
85	Myeloperoxidase-Related Chlorination Activity Is Positively Associated with Circulating Ceruloplasmin in Chronic Heart Failure Patients: Relationship with Neurohormonal, Inflammatory, and Nutritional Parameters. BioMed Research International, 2015, 2015, 1-10.	1.9	12
86	An update on hypertensive emergencies and urgencies. Journal of Cardiovascular Medicine, 2015, 16, 372-382.	1.5	60
87	Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis. FASEB Journal, 2015, 29, 4614-4628.	0.5	60
88	Role of matrix metalloproteinases in cholestasis and hepatic ischemia/reperfusion injury: A review. World Journal of Gastroenterology, 2015, 21, 12114.	3.3	24
89	Lung Matrix Metalloproteinase Activation following Partial Hepatic Ischemia/Reperfusion Injury in Rats. Scientific World Journal, The, 2014, 2014, 1-10.	2.1	11
90	Lobe-Specific Heterogeneity in Asymmetric Dimethylarginine and Matrix Metalloproteinase Levels in a Rat Model of Obstructive Cholestasis. BioMed Research International, 2014, 2014, 1-8.	1.9	16

#	Article	IF	Citations
91	Cardiovascular risk assessment in low-resource settings. Journal of Hypertension, 2014, 32, 951-960.	0.5	73
92	Simulation-guided cardiac auscultation improves medical students' clinical skills: the Pavia pilot experience. Internal and Emergency Medicine, 2014, 9, 165-172.	2.0	22
93	Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case–control study on 174 patients. Leukemia, 2014, 28, 2311-2316.	7.2	113
94	Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach. Haematologica, 2014, 99, 743-750.	3.5	138
95	Prognostic value of depressed midwall systolic function in cardiac light-chain amyloidosis. Journal of Hypertension, 2014, 32, 1121-1131.	0.5	20
96	Effects of Tafamidis on Transthyretin Stabilization and Clinical Outcomes in Patients with Non-Val30Met Transthyretin Amyloidosis. Journal of Cardiovascular Translational Research, 2013, 6, 1011-1020.	2.4	122
97	High ^{99m} Tc-DPD myocardial uptake in a patient with apolipoprotein Al-related amyloidotic cardiomyopathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2013, 20, 48-51.	3.0	16
98	Early development of metabolic syndrome in patients subjected to lung transplantation. Clinical Transplantation, 2013, 27, E237-43.	1.6	21
99	Pulse pressure and heart rate in patients with metabolic syndrome across Europe: insights from the GOOD survey. Journal of Human Hypertension, 2013, 27, 412-416.	2.2	22
100	Prognostic value of fragmented QRS in cardiac AL amyloidosis. International Journal of Cardiology, 2013, 167, 2156-2161.	1.7	48
101	A Multimarker Study of Degenerative Aortic Valve Disease: Stenoinsufficiency Shows More Indices of Bad Prognosis. Cardiology, 2013, 124, 126-137.	1.4	8
102	Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. European Heart Journal, 2013, 34, 520-528.	2.2	252
103	Alterations in Early Filling Dynamics Predict the Progression of Compensated Pressure Overload Hypertrophy to Heart Failure Better than Abnormalities in Midwall Systolic Shortening. Clinical and Experimental Hypertension, 2013, 35, 401-411.	1.3	7
104	Diagnostic and Prognostic Value of Low QRS Voltages in Cardiac AL Amyloidosis. Annals of Noninvasive Electrocardiology, 2013, 18, 271-280.	1.1	75
105	Prevalence and Prognostic Value of Conduction Disturbances at the Time of Diagnosis of Cardiac AL Amyloidosis. Annals of Noninvasive Electrocardiology, 2013, 18, 327-335.	1.1	40
106	As we cannot afford to renounce to new generation echocardiography in systemic amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2013, 20, 195-196.	3.0	0
107	A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. Haematologica, 2013, 98, 433-436.	3.5	65
108	Hypertension-related target organ damage. Journal of Hypertension, 2013, 31, 1083-1085.	0.5	11

#	Article	IF	CITATIONS
109	Hypertension and stable coronary artery disease. Journal of Cardiovascular Medicine, 2013, 14, 545-552.	1.5	5
110	From hypertension to hypertrophy to heart failure. Journal of Hypertension, 2013, 31, 474-476.	0.5	10
111	Lobe-Specific Heterogeneity and Matrix Metalloproteinase Activation after Ischemia/Reperfusion Injury in Rat Livers. Toxicologic Pathology, 2012, 40, 722-730.	1.8	27
112	Hypertension and acute myocardial infarction. Journal of Cardiovascular Medicine, 2012, 13, 194-202.	1.5	54
113	The repertoire of \hat{l} » light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44. Blood, 2012, 119, 144-150.	1.4	98
114	Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2012, 19, 34-36.	3.0	184
115	Right ventricular function in AL amyloidosis: characteristics and prognostic implication. European Heart Journal Cardiovascular Imaging, 2012, 13, 416-422.	1.2	97
116	Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. American Journal of Hematology, 2012, 87, 465-471.	4.1	95
117	Functional correlates of N-terminal natriuretic peptide type B (NT-proBNP) response to therapy in cardiac light chain (AL) amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 96-97.	3.0	4
118	Distinct mechanisms for diastolic dysfunction in diabetes mellitus and chronic pressure-overload. Basic Research in Cardiology, 2011, 106, 801-814.	5.9	54
119	Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 216-221.	3.0	26
120	Prevention of myocardial fibrosis by $\langle i \rangle N \langle i \rangle$ -acetyl-seryl-aspartyl-lysyl-proline in diabetic rats. Clinical Science, 2010, 118, 211-220.	4.3	31
121	The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood, 2010, 116, 3426-3430.	1.4	184
122	Imaging of Systemic Amyloidosis. , 2010, , 15-32.		5
123	Systemic Cardiac Amyloidoses. Circulation, 2009, 120, 1203-1212.	1.6	622
124	Inter-regional comparisons of the prevalence of cardiometabolic risk factors in patients with hypertension in Europe: the GOOD survey. Journal of Human Hypertension, 2009, 23, 316-324.	2.2	18
125	Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide. Annals of Hematology, 2009, 88, 347-350.	1.8	67
126	Blood pressure control and components of the metabolic syndrome: the GOOD survey. Cardiovascular Diabetology, 2009, 8, 51.	6.8	33

#	Article	IF	Citations
127	Noninvasive assessment of cardiac structure and function in Apolipoprotein A-I amyloidosis (Leu75Pro). International Journal of Cardiology, 2009, 137, S82.	1.7	0
128	Prevention of Recurrent Lone Atrial Fibrillation by the Angiotensin-II Converting Enzyme Inhibitor Ramipril in Normotensive Patients. Journal of the American College of Cardiology, 2009, 53, 24-29.	2.8	99
129	A Phase II Trial of Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) in Previously Treated Patients with AL Amyloidosis Blood, 2009, 114, 2863-2863.	1.4	5
130	Treatment with Oral Melphalan and Dexamethasone of An Extended Patient Population with AL Amyloidosis Blood, 2009, 114, 3889-3889.	1.4	3
131	High-Sensitivity Troponin Assay Improves the Detection of Cardiac Involvement in AL Amyloidosis and Is the Most Powerful Prognostic Determinant Blood, 2009, 114, 1782-1782.	1.4	0
132	Gender-related risk of myocardial involvement in systemic amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2008, 15, 40-48.	3.0	83
133	Direct Renin Inhibition. Hypertension, 2008, 52, 1019-1021.	2.7	3
134	Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: the Global Cardiometabolic Risk Profile in Patients with hypertension disease survey. Journal of Hypertension, 2008, 26, 2064-2070.	0.5	82
135	Importance of the echocardiographic evaluation of right ventricular function in patients with AL amyloidosis. European Journal of Heart Failure, 2007, 9, 808-813.	7.1	61
136	Determinants of left ventricular mass in hypertensive heart disease: a complex interplay between volume, pressure, systolic function and genes. Journal of Hypertension, 2007, 25, 1341-1342.	0.5	7
137	Adenosine A1 receptor expression during the transition from compensated pressure overload hypertrophy to heart failure. Journal of Hypertension, 2007, 25, 449-454.	0.5	6
138	Matrix Metalloprotease Activity Is Enhanced in the Compensated but Not in the Decompensated Phase of Pressure Overload Hypertrophy. American Journal of Hypertension, 2007, 20, 663-669.	2.0	24
139	Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood, 2006, 107, 3854-3858.	1.4	266
140	Electrocardiographic â€~strain' pattern in left ventricular hypertrophy: electrical waves or mechanical function?. Journal of Hypertension, 2006, 24, 1925-1926.	0.5	0
141	Unusual Manifestations of Disseminated Neoplasia at Presentation:. American Journal of Clinical Oncology: Cancer Clinical Trials, 2006, 29, 102-103.	1.3	8
142	Survival Benefits of Different Antiadrenergic Interventions in Pressure Overload Left Ventricular Hypertrophy/Failure. Hypertension, 2006, 48, 93-97.	2.7	21
143	The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood, 2005, 105, 2949-2951.	1.4	207
144	Peripheral blood progenitor cell mobilization and collection in 42 patients with primary systemic amyloidosis. Transfusion, 2005, 45, 1729-1734.	1.6	15

#	Article	IF	CITATIONS
145	Sympathectomy or Doxazosin, But Not Propranolol, Blunt Myocardial Interstitial Fibrosis in Pressure-Overload Hypertrophy. Hypertension, 2005, 46, 1213-1218.	2.7	7 5
146	The potential advantage of omapatrilat: dual anti-fibrotic and anti-inflammatory effects in one single molecule. Journal of Hypertension, 2005, 23, 273-275.	0.5	2
147	Cost-effectiveness in Italy of preventive treatment with ramipril in patients at high risk of cardiovascular events. Current Medical Research and Opinion, 2005, 21, 913-921.	1.9	8
148	Adenosine A1 and A2A receptor cross-talk during ageing in the rat myocardium. Experimental Gerontology, 2003, 38, 855-861.	2.8	10
149	Serum N-Terminal Pro–Brain Natriuretic Peptide Is a Sensitive Marker of Myocardial Dysfunction in AL Amyloidosis. Circulation, 2003, 107, 2440-2445.	1.6	456
150	Cardiac mast cells in the transition to heart failure. Journal of Hypertension, 2003, 21, 1823-1825.	0.5	16
151	Preservation of the Baroreceptor Heart Rate Reflex by Chemical Sympathectomy in Experimental Heart Failure. Circulation, 2002, 106, 866-872.	1.6	23
152	Nitric Oxide-Dependent Vasodilation and the Regulation of Arterial Blood Pressure. Journal of Cardiovascular Pharmacology, 2001, 38, S19-S22.	1.9	11
153	Antiadrenergic Effects of Adenosine in Pressure Overload Hypertrophy. Hypertension, 2001, 37, 862-868.	2.7	23
154	Midwall Mechanics Are Improved After Regression of Hypertensive Left Ventricular Hypertrophy and Normalization of Chamber Geometry. Circulation, 2001, 103, 678-683.	1.6	75
155	Enhanced vascular reactivity in the sympathectomized rat. Journal of Hypertension, 2000, 18, 1041-1049.	0.5	19
156	Nonischemic End-Systolic Performance. Cardiology, 1999, 91, 14-24.	1.4	1
157	Mechanism of binocular interaction in refraction errors: study using pattern-reversal visual evoked potentials. Documenta Ophthalmologica, 1999, 98, 139-151.	2.2	8
158	Adenosine Mediates Sustained Adrenergic Desensitization in the Rat Heart via Activation of Protein Kinase C. Circulation Research, 1998, 83, 761-771.	4.5	33
159	Experience from controlled trials of physical training in chronic heart failure. Protocol and patient factors in effectiveness in the improvement in exercise tolerance. European Heart Journal, 1998, 19, 466-475.	2.2	199
160	Effects of chronic adenosine uptake blockade on adrenergic responsiveness and left ventricular chamber function in pressure overload hypertrophy in the rat. Journal of Hypertension, 1998, 16, 1813-1822.	0.5	50
161	Lack of autonomic contributions to tonic nitric oxide-mediated vasodilatation in unanesthetized free-moving rats. Journal of Hypertension, 1998, 16, 55-61.	0.5	21
162	Effects of Preload, Afterload and Inotropy on Dynamics of Ischemic Segmental Wall Motion. Journal of the American College of Cardiology, 1997, 29, 846-855.	2.8	13

#	Article	IF	CITATIONS
163	Influence of residual ischaemia on heart rate variability after myocardial infarction. European Heart Journal, 1997, 18, 78-83.	2.2	21
164	Effects of preload on regional nonischemic end-systolic performance. Coronary Artery Disease, 1996, 7, 797-806.	0.7	1
165	Dynamic right and left ventricular interactions in the rabbit: Simultaneous measurement of ventricular pressure-volume loops. Journal of Critical Care, 1996, 11, 65-76.	2.2	24
166	Reproducibility of ultrasound assessment of common carotid and femoral artery compliance and distensibility in the anesthetized rat. Journal of Hypertension, 1995, 13, 1689???1694.	0.5	2
167	Effect of pharmacologically induced mydriasis on the normal variability of retinal oscillatory potentials in man. Acta Ophthalmologica, 1995, 73, 133-138.	0.3	1
168	Regional nonischemic performance as assessed by end-systolic measures of shortening and thickening. Journal of the American College of Cardiology, 1994, 24, 1797-1805.	2.8	10
169	Assessment of regional myocardial performance with end-systolic pressure length and thickness relationships. International Journal of Cardiology, 1993, 42, 197-216.	1.7	2
170	Continuous monitoring of right ventricular volume changes using a conductance catheter in the rabbit. Journal of Applied Physiology, 1992, 73, 1770-1775.	2.5	25
171	Time course of pressure and flow in ascending aorta during ejection. International Journal of Cardiology, 1991, 30, 169-179.	1.7	1
172	Critical Evaluation of Pharmacodynamic Tests for Cardiovascular Diagnosis: An Expert System Approach. American Journal of Noninvasive Cardiology, 1990, 4, 266-275.	0.1	2
173	Evidence for an intrinsic mechanism regulating heart rate variability in the transplanted and the intact heart during submaximal dynamic exercise?. Cardiovascular Research, 1990, 24, 969-981.	3.8	203
174	Acute haemodynamic effects of ibopamine and dopamine on isovolumic relaxation. European Journal of Pharmacology, 1989, 164, 415-424.	3.5	5
175	Load dependence of isovolumic relaxation in intact heart: facts or artifacts?. Cardiovascular Research, 1988, 22, 47-54.	3.8	8
176	Atrial Fibrillation and the Renin-Angiotensin-Aldosterone System. , 0, , .		2